10x Genomics TXG has been analyzed by 12 analysts within the final three months, revealing a various vary of views from bullish to bearish.
The desk under affords a condensed view of their latest rankings, showcasing the altering sentiments over the previous 30 days and evaluating them to the previous months.
| Bullish | Considerably Bullish | Detached | Considerably Bearish | Bearish | |
|---|---|---|---|---|---|
| Complete Rankings | 5 | 3 | 4 | 0 | 0 |
| Final 30D | 1 | 0 | 0 | 0 | 0 |
| 1M In the past | 0 | 0 | 1 | 0 | 0 |
| 2M In the past | 0 | 1 | 0 | 0 | 0 |
| 3M In the past | 4 | 2 | 3 | 0 | 0 |
Offering deeper insights, analysts have established 12-month value targets, indicating a mean goal of $15.5, together with a excessive estimate of $26.00 and a low estimate of $9.00. A unfavourable shift in sentiment is obvious as analysts have decreased the common value goal by 20.51%.
Exploring Analyst Rankings: An In-Depth Overview
The evaluation of latest analyst actions sheds mild on the notion of 10x Genomics by monetary consultants. The next abstract presents key analysts, their latest evaluations, and changes to rankings and value targets.
| Analyst | Analyst Agency | Motion Taken | Score | Present Value Goal | Prior Value Goal |
|---|---|---|---|---|---|
| Kyle Mikson | Canaccord Genuity | Lowers | Purchase | $15.00 | $18.00 |
| Rachel Vatnsdal | JP Morgan | Lowers | Impartial | $9.00 | $12.00 |
| Luke Sergott | Barclays | Lowers | Obese | $12.00 | $15.00 |
| Patrick Donnelly | Citigroup | Lowers | Purchase | $15.00 | $20.00 |
| Tejas Savant | Morgan Stanley | Lowers | Obese | $26.00 | $28.00 |
| Luke Sergott | Barclays | Lowers | Obese | $15.00 | $18.00 |
| Kyle Mikson | Canaccord Genuity | Lowers | Purchase | $18.00 | $20.00 |
| Patrick Donnelly | Citigroup | Lowers | Purchase | $20.00 | $23.00 |
| Rachel Vatnsdal | JP Morgan | Lowers | Impartial | $12.00 | $14.00 |
| Dan Leonard | UBS | Lowers | Impartial | $14.00 | $20.00 |
| Daniel Arias | Stifel | Lowers | Purchase | $18.00 | $21.00 |
| Mike Kratky | Leerink Companions | Lowers | Market Carry out | $12.00 | $25.00 |
Key Insights:
- Motion Taken: Analysts adapt their suggestions to altering market situations and firm efficiency. Whether or not they ‘Preserve’, ‘Increase’ or ‘Decrease’ their stance, it displays their response to latest developments associated to 10x Genomics. This data offers a snapshot of how analysts understand the present state of the corporate.
- Score: Offering a complete evaluation, analysts supply qualitative assessments, starting from ‘Outperform’ to ‘Underperform’. These rankings mirror expectations for the relative efficiency of 10x Genomics in comparison with the broader market.
- Value Targets: Analysts predict actions in value targets, providing estimates for 10x Genomics’s future worth. Inspecting the present and prior targets affords insights into analysts’ evolving expectations.
For helpful insights into 10x Genomics’s market efficiency, take into account these analyst evaluations alongside essential monetary indicators. Keep well-informed and make prudent choices utilizing our Rankings Desk.
Keep updated on 10x Genomics analyst rankings.
If you’re desirous about following small-cap inventory information and efficiency you can begin by monitoring it right here.
Delving into 10x Genomics’s Background
10x Genomics Inc is a life science expertise firm primarily based in the USA. Its options embrace devices, consumables, and software program for analyzing organic programs. The corporate’s built-in options embrace devices, consumables, and software program for analyzing organic programs at a decision and scale that matches the complexity of biology. Its product choices embrace a Chromium platform comprising microfluidic chips and associated consumables, Chromium X sequence, Visium and Xenium platforms, and others, that are predominantly used for the research of organic elements. Geographically, the corporate derives most income from the USA and the remainder from Americas (excluding the USA), Europe, Center East and Africa, China, and Asia-Pacific (excluding China).
10x Genomics’s Financial Influence: An Evaluation
Market Capitalization: With restricted market capitalization, the corporate is positioned under trade averages. This displays a smaller scale relative to friends.
Income Development: 10x Genomics’s income progress over a interval of 3M has confronted challenges. As of 31 March, 2025, the corporate skilled a income decline of roughly -6.14%. This means a lower within the firm’s top-line earnings. As in comparison with opponents, the corporate encountered difficulties, with a progress price decrease than the common amongst friends within the Well being Care sector.
Internet Margin: The corporate’s internet margin is under trade benchmarks, signaling potential difficulties in reaching sturdy profitability. With a internet margin of -22.18%, the corporate might have to deal with challenges in efficient value management.
Return on Fairness (ROE): 10x Genomics’s ROE is under trade requirements, pointing in the direction of difficulties in effectively using fairness capital. With an ROE of -4.85%, the corporate might encounter challenges in delivering passable returns for shareholders.
Return on Property (ROA): 10x Genomics’s ROA is under trade requirements, pointing in the direction of difficulties in effectively using property. With an ROA of -3.77%, the corporate might encounter challenges in delivering passable returns from its property.
Debt Administration: 10x Genomics’s debt-to-equity ratio is under the trade common. With a ratio of 0.11, the corporate depends much less on debt financing, sustaining a more healthy stability between debt and fairness, which could be seen positively by traders.
The Core of Analyst Rankings: What Each Investor Ought to Know
Analyst rankings function important indicators of inventory efficiency, offered by consultants in banking and monetary programs. These specialists diligently analyze firm monetary statements, take part in convention calls, and have interaction with insiders to generate quarterly rankings for particular person shares.
Some analysts publish their predictions for metrics equivalent to progress estimates, earnings, and income to supply further steerage with their rankings. When utilizing analyst rankings, it is very important remember the fact that inventory and sector analysts are additionally human and are solely providing their opinions to traders.
If you wish to maintain monitor of which analysts are outperforming others, you may view up to date analyst rankings alongside withanalyst success scores in Benzinga Professional.
Which Shares Are Analysts Recommending Now?
Benzinga Edge offers you instantaneous entry to all main analyst upgrades, downgrades, and value targets. Type by accuracy, upside potential, and extra. Click on right here to remain forward of the market.
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
